Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan

MicroRNAs are non-coding RNAs that can block mRNA translation and influence mRNA stability. Recent evidence indicates that miRNA variations can affect drug resistance, efficacy, and metabolism, opening new avenues of pharmacogenomics research. We investigated associations between polymorphisms in both miRNA-containing genomic regions (primary and precursor miRNA) and in genes related to miRNA biogenesis with clinical outcome in metastatic colorectal cancer (mCRC) patients treated with 5-fluorouracil and irinotecan (CPT-11). Eighteen single-nucleotide polymorphisms (SNPs) were analyzed in 61 patients. A significant association with tumor response and time to progression (TTP) was found for SNP rs7372209 in pri-miR26a-1 (P=0.041 and P=0.017, respectively). The genotypes CC and CT were favorable when compared with the TT variant genotype. In addition, SNP rs1834306, located in the pri-miR-100 gene, significantly correlated with a longer TTP (P=0.04). In the miRNA-biogenesis pathway, a trend was identified between SNP rs11077 in the exportin-5 gene and disease control rate (P=0.076). This study is the first to suggest a relationship between treatment outcome and SNPs in the miRNA-biogenesis machinery, in both primary and precursor miRNAs. Our results suggest that miRNA polymorphic variants might be useful predictors of clinical outcome in mCRC patients treated with 5-fluorouracil and CPT-11 combination.

[1]  B. Cullen.  Transcription and processing of human microRNA precursors. , 2004, Molecular cell.

[2]  Tushar Patel,et al.  Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. , 2006, Gastroenterology.

[3]  C. Heldin,et al.  Expression of Smad proteins in human colorectal cancer , 1999, International journal of cancer.

[4]  J. Bertino,et al.  MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. , 2009, Pharmacogenomics.

[5]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[6]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[7]  M. Choti,et al.  Urgent need for a new staging system in advanced colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[9]  M. Mann,et al.  miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. , 2002, Genes & development.

[10]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[11]  W. Sellers,et al.  PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. , 2009, Cancer research.

[12]  J. Pollack,et al.  MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. , 2008, Blood.

[13]  S. Lowe,et al.  A microRNA polycistron as a potential human oncogene , 2005, Nature.

[14]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[15]  Yuanqing Ye,et al.  Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. , 2008, Cancer research.

[16]  Kathryn A. O’Donnell,et al.  Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model , 2009, Cell.

[17]  F. Costa,et al.  The impact of microRNAs and alternative splicing in pharmacogenomics , 2009, The Pharmacogenomics Journal.

[18]  Reuven Agami,et al.  The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. , 2009, Genes & development.

[19]  Bo Song,et al.  miR-192 Regulates Dihydrofolate Reductase and Cellular Proliferation through the p53-microRNA Circuit , 2008, Clinical Cancer Research.

[20]  Jian Gu,et al.  Single Nucleotide Polymorphisms of microRNA Machinery Genes Modify the Risk of Renal Cell Carcinoma , 2008, Clinical Cancer Research.

[21]  Xabier Agirre,et al.  Epigenetic regulation of microRNA expression in colorectal cancer , 2009, International journal of cancer.

[22]  R. Shiekhattar,et al.  TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing , 2005, Nature.

[23]  Yogendra P. Chaubey.  Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment , 1993 .

[24]  Sanghyuk Lee,et al.  MicroRNA genes are transcribed by RNA polymerase II , 2004, The EMBO journal.

[25]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[26]  Wen-Hsiung Li,et al.  Human polymorphism at microRNAs and microRNA target sites , 2007, Proceedings of the National Academy of Sciences.

[27]  Peng Jin,et al.  Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. , 2007, Human molecular genetics.

[28]  J. Waldron,et al.  Significance of Plk1 regulation by miR‐100 in human nasopharyngeal cancer , 2009, International journal of cancer.

[29]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[30]  Lin Zhang,et al.  MicroRNAs: A New Insight into Cancer Genome , 2006, Cell cycle.

[31]  Charles E. Vejnar,et al.  Human polymorphism at microRNAs and microRNA target sites. , 2013 .

[32]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[33]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[34]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[35]  N. Iwai,et al.  Polymorphisms in human pre-miRNAs. , 2005, Biochemical and biophysical research communications.

[36]  Guiliang Tang,et al.  siRNA and miRNA: an insight into RISCs. , 2005, Trends in biochemical sciences.

[37]  Jackeline Agorreta,et al.  microRNA-451 Regulates Macrophage Migration Inhibitory Factor Production and Proliferation of Gastrointestinal Cancer Cells , 2009, Clinical Cancer Research.

[38]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  W. Weichert,et al.  Polo-like kinase 1 expression is a prognostic factor in human colon cancer. , 2005, World journal of gastroenterology.

[40]  V. Kim,et al.  The nuclear RNase III Drosha initiates microRNA processing , 2003, Nature.

[41]  K. Helin,et al.  E2F7, a novel E2F featuring DP‐independent repression of a subset of E2F‐regulated genes , 2003, The EMBO journal.

[42]  B. Cullen,et al.  Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs. , 2005, RNA.

[43]  B. Cullen,et al.  MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Anton J. Enright,et al.  Human MicroRNA Targets , 2004, PLoS biology.

[45]  G. Hutvagner,et al.  A microRNA in a Multiple-Turnover RNAi Enzyme Complex , 2002, Science.

[46]  Adrian V. Lee,et al.  The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. , 2008, Frontiers in bioscience : a journal and virtual library.

[47]  Elizabeth M. Smigielski,et al.  dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..

[48]  J. Haier,et al.  MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. , 2010, European journal of cancer.

[49]  B. Cullen,et al.  Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. , 2003, Genes & development.

[50]  E. Feingold,et al.  Decreased expression of miR‐125b and miR‐100 in oral cancer cells contributes to malignancy , 2009, Genes, chromosomes & cancer.